Emcure’s Initiatives in
Anemia Management
Dr. P. Bhandari, M.D.
1
Emcure
 Research driven pharmaceutical company
Therapeutic areas
 Responsible corporate citizen
Anemia
 giving back to society from which it profits
AIDS
Cardiology
Nephrology
Oncology
Gynecology
Diabetes
Neurology
We bring difference in lives
Orthopedics
Gastroenterology
2
Anemia – a global problem
According to a survey conducted by NFHS, the prevalence of anaemia in young girls
aged between 15-24 years is 56% with higher rates in rural than in urban India.
3
Anemia affects all
 Mother
 Pre-term delivery
 Fetal and maternal mortality
 Low birth weigh baby
 Child
 Impaired mental function
 Increased infections
 Frequent diarrhea
4
Anemia – signs/symptoms
 Fatigue (very common)
 Weakness (very common)
 Dizziness
 Shortness of breath
 Irritability
 Lack of concentration
 Pale skin and tongue
 Brittle nails
 Low hemoglobin
Iron deficiency anaemia with depapillated
tongue, depigmentation of the upper lip
and epithelial erosion of the lower lip
5
Emcure in Anaemia management
 Innovative oral iron products:
 Ferrous ascorbate tablets, suspension,
etc.
 State of the art parenteral iron
products:
 Iron sucrose injection
 Ferric carboxymaltose injection
 Biotechnology products:
 Erythropoietin
6
Ferrous Ascorbate




Leaders in the ferrous ascorbate market
Offering own R&D ferrous ascorbate
Granted Indian Patent
The best oral iron so far:
 Maximum bioavailability of up to 43%
 Excellent tolerability
 Prevents inhibitory action of dietary phytates etc
 Proven safety and efficacy
 Dose: 100 mg elemental iron daily for adults
7
Why Ferrous Ascorbate?
Inhibitors
 The absorption of iron from ordinary iron
supplements is approximately 10% or less
 This is due to presence of inhibitory ligands
like phytates, tannins, phosphates etc in food
Facilitators
 The presence of ascorbate facilitates
absorption by preventing the action of these
inhibitory ligands
 This increase absorption of iron from ferrous
ascorbate up to 43%
8
When oral iron may not be sufficient?
 In severe anemia that will require very long time to




correct
Very low iron stores that need quick replenishment
In renal failure patients who do not respond to oral
iron
In menorrhagia-associated severe iron-deficiency
anemia
In anemia associated with cancer
 Parenteral (IV) iron
9
Iron Sucrose Injection
 The dominant IV iron for anaemia
management
 Does not have risk of dextran-induced
hypersensitivity
 Used by both nephrologists and
obstetricians
 Dose: 100 mg by slow IV bolus x max thrice
weekly, or 100-200 mg IV infusion x max
thrice weekly, to replenish cumulative deficit
10
Ferric Carboxymaltose Injection
 The latest IV iron
 Introduced first in India by Emcure
 Offers feasibility of total dose infusion
of 1g in 15 min
 No dextran-type hypersensitivity
 Safe & effective in different
indications
11
Erythropoietin
 Manufactured in Gennova
Biopharmaceuticals facility of Emcure
 Matching European Pharmacopoeia
standards
 Used by nephrologists in renal anemia
 Used by obstetricians in EPO-deficient
IDA in pregnancy
12
FOGSI – Emcure Social Responsibility
13
Emcure’s Corporate Social Responsibility
14
Emcure’s Corporate Social Responsibility
15
Emcure’s Corporate Social Responsibility
16
Emcure’s Corporate Social Responsibility
17
FOGSI-Emcure Publications
http://haemoglobin-anaemia.com/fogsipublication.asp
18
Emcure in Anemia Management
 Latest research and development
 Quality products
 Education, awareness and support
 through CSR activities
We bring difference in lives
19
Emcure’s websites
 www.emcure.co.in
 http://haemoglobin-anaemia.com
20